\n \n\n \n \n \n \n \n Is sepsis treatment heating up?.\n \n \n \n\n\n \n Young, P. J.\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 21(2): 85–86. June 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{young_is_2019,\n\ttitle = {Is sepsis treatment heating up?},\n\tvolume = {21},\n\tissn = {1441-2772},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Young, Paul J.},\n\tmonth = jun,\n\tyear = {2019},\n\tpmid = {31142237},\n\tnote = {Number: 2},\n\tkeywords = {Heating, Humans, Sepsis},\n\tpages = {85--86},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n When less is more in the active management of elevated body temperature of ICU patients.\n \n \n \n \n\n\n \n Young, P. J.; and Prescott, H. C.\n\n\n \n\n\n\n Intensive Care Medicine, 45(9): 1275–1278. September 2019.\n Number: 9\n\n\n\n
\n\n\n\n \n \n $\"When$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_when_2019,\n\ttitle = {When less is more in the active management of elevated body temperature of {ICU} patients},\n\tvolume = {45},\n\tissn = {0342-4642, 1432-1238},\n\turl = {http://link.springer.com/10.1007/s00134-019-05668-0},\n\tdoi = {10.1007/s00134-019-05668-0},\n\tlanguage = {en},\n\tnumber = {9},\n\turldate = {2020-08-23},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Young, Paul J. and Prescott, Hallie C.},\n\tmonth = sep,\n\tyear = {2019},\n\tnote = {Number: 9},\n\tpages = {1275--1278},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Vasopressin in septic shock: what we know and where to next?.\n \n \n \n \n\n\n \n Young, P. J.; Delaney, A.; and Venkatesh, B.\n\n\n \n\n\n\n Intensive Care Medicine, 45(6): 902–903. June 2019.\n Number: 6\n\n\n\n
\n\n\n\n \n \n $\"Vasopressin$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_vasopressin_2019,\n\ttitle = {Vasopressin in septic shock: what we know and where to next?},\n\tvolume = {45},\n\tissn = {0342-4642, 1432-1238},\n\tshorttitle = {Vasopressin in septic shock},\n\turl = {http://link.springer.com/10.1007/s00134-019-05642-w},\n\tdoi = {10.1007/s00134-019-05642-w},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2020-08-23},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Young, Paul J. and Delaney, Anthony and Venkatesh, Balasubramanian},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 6},\n\tpages = {902--903},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Balanced Crystalloids or 0.9% Saline in Sepsis. Beyond Reasonable Doubt?.\n \n \n \n \n\n\n \n Young, P. J.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 200(12): 1456–1458. December 2019.\n Number: 12\n\n\n\n
\n\n\n\n \n \n $\"Balanced$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_balanced_2019,\n\ttitle = {Balanced {Crystalloids} or 0.9\\% {Saline} in {Sepsis}. {Beyond} {Reasonable} {Doubt}?},\n\tvolume = {200},\n\tissn = {1073-449X, 1535-4970},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.201908-1669ED},\n\tdoi = {10.1164/rccm.201908-1669ED},\n\tlanguage = {en},\n\tnumber = {12},\n\turldate = {2020-08-23},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Young, Paul J.},\n\tmonth = dec,\n\tyear = {2019},\n\tnote = {Number: 12},\n\tpages = {1456--1458},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Fever control in critically ill adults. An individual patient data meta-analysis of randomised controlled trials.\n \n \n \n \n\n\n \n Young, P. J.; Bellomo, R.; Bernard, G. R.; Niven, D. J.; Schortgen, F.; Saxena, M.; Beasley, R.; and Weatherall, M.\n\n\n \n\n\n\n Intensive Care Medicine, 45(4): 468–476. April 2019.\n Number: 4\n\n\n\n
\n\n\n\n \n \n $\"Fever$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_fever_2019,\n\ttitle = {Fever control in critically ill adults. {An} individual patient data meta-analysis of randomised controlled trials},\n\tvolume = {45},\n\tissn = {0342-4642, 1432-1238},\n\turl = {http://link.springer.com/10.1007/s00134-019-05553-w},\n\tdoi = {10.1007/s00134-019-05553-w},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2020-08-23},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Young, Paul J. and Bellomo, Rinaldo and Bernard, Gordon R. and Niven, Daniel J. and Schortgen, Frederique and Saxena, Manoj and Beasley, Richard and Weatherall, Mark},\n\tmonth = apr,\n\tyear = {2019},\n\tnote = {Number: 4},\n\tpages = {468--476},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n O2, do we know what to do?.\n \n \n \n\n\n \n Young, P. J.; Bagshaw, S. M.; Bailey, M.; Bellomo, R.; Mackle, D.; Pilcher, D.; Landoni, G.; Nichol, A.; and Martin, D.\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 21(4): 230–232. December 2019.\n Number: 4\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n\n\n\n

\n

@article{young_o2_2019,\n\ttitle = {O2, do we know what to do?},\n\tvolume = {21},\n\tissn = {1441-2772},\n\tlanguage = {eng},\n\tnumber = {4},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Young, Paul J. and Bagshaw, Sean M. and Bailey, Michael and Bellomo, Rinaldo and Mackle, Diane and Pilcher, David and Landoni, Giovanni and Nichol, Alistair and Martin, Daniel},\n\tmonth = dec,\n\tyear = {2019},\n\tpmid = {31778627},\n\tnote = {Number: 4},\n\tkeywords = {Humans, Oxygen},\n\tpages = {230--232},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n The Risk of Hyperoxemia in ICU Patients. Much Ado About O2.\n \n \n \n\n\n \n Young, P. J.; and Bellomo, R.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 200(11): 1333–1335. 2019.\n Number: 11\n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{young_risk_2019,\n\ttitle = {The {Risk} of {Hyperoxemia} in {ICU} {Patients}. {Much} {Ado} {About} {O2}},\n\tvolume = {200},\n\tissn = {1535-4970},\n\tdoi = {10.1164/rccm.201909-1751ED},\n\tlanguage = {eng},\n\tnumber = {11},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Young, Paul J. and Bellomo, Rinaldo},\n\tyear = {2019},\n\tpmid = {31526323},\n\tpmcid = {PMC6884040},\n\tnote = {Number: 11},\n\tkeywords = {Blood Gas Analysis, Cohort Studies, Critical Illness, Humans, Intensive Care Units, Oxygen},\n\tpages = {1333--1335},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Characteristics, management and outcomes of patients with acute liver failure admitted to Australasian intensive care units.\n \n \n \n\n\n \n Warrillow, S.; Tibballs, H.; Bailey, M.; McArthur, C.; Lawson-Smith, P.; Prasad, B.; Anstey, M.; Venkatesh, B.; Dashwood, G.; Walsham, J.; Holt, A.; Wiersema, U.; Gattas, D.; Zoeller, M.; Garcia Alvarez, M.; Bellomo, R.; and Australasian Management of Acute Liver Failure Investigators (AMALFI)\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 21(3): 188–199. September 2019.\n Number: 3\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{warrillow_characteristics_2019,\n\ttitle = {Characteristics, management and outcomes of patients with acute liver failure admitted to {Australasian} intensive care units},\n\tvolume = {21},\n\tissn = {1441-2772},\n\tabstract = {OBJECTIVE: Acute liver failure (ALF) leads to severe illness and usually requires admission to the intensive care unit (ICU). Despite its importance, little is known about patients with ALF in Australia and New Zealand.\nDESIGN: Binational observational study to evaluate the aetiology, baseline characteristics, patterns of illness, management, and outcomes for patients with ALF admitted to Australian and New Zealand ICUs.\nSETTING: All six Australian and New Zealand ICUs in liver transplant centres submitted de-identified data for ten or more consecutive patients with ALF. Data were obtained from the clinical record and included baseline characteristics, aetiology, mode of presentation, illness severity, markers of liver failure, critical care interventions, utilisation of transplantation, and hospital outcome.\nRESULTS: We studied 62 patients with ALF. Paracetamol overdose (POD) was the underlying cause of ALF in 53\\% of patients (33/62), with staggered ingestion in 42\\% of patients (14/33). Among patients with POD, 70\\% (23/33) were young women, most had psychiatric diagnoses, and most presented relatively early with overt liver failure. This group were transplanted in only 6\\% of cases (2/33) and had an overall mortality of 24\\% (8/33). The remaining patients with ALF had less common conditions, such as hepatitis B and non-paracetamol drug-induced ALF. These patients presented later and exhibited less extreme evidence of acute hepatic necrosis. Transplantation was performed in 38\\% of patients (11/29) in this subgroup. The mortality of nontransplanted non-POD patients was 56\\% (10/18). Illness severity at ICU admission, initial requirement for organ support therapies and length of hospital stay were similar between patients with POD and non-POD ALF.\nCONCLUSION: POD is the major cause of ALF in Australian and New Zealand liver transplant centres and is a unique and separate form of ALF. It has a much lower associated mortality and treatment with liver transplantation than non-POD ALF. Non-POD patients have a poor prognosis in the absence of transplantation.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Warrillow, Stephen and Tibballs, Heath and Bailey, Michael and McArthur, Colin and Lawson-Smith, Pia and Prasad, Bheemasenachar and Anstey, Matthew and Venkatesh, Balasubramanian and Dashwood, Gemma and Walsham, James and Holt, Andrew and Wiersema, Ubbo and Gattas, David and Zoeller, Matthew and Garcia Alvarez, Mercedes and Bellomo, Rinaldo and {Australasian Management of Acute Liver Failure Investigators (AMALFI)}},\n\tmonth = sep,\n\tyear = {2019},\n\tpmid = {31462206},\n\tnote = {Number: 3},\n\tkeywords = {Acetaminophen, Adolescent, Adult, Analgesics, Non-Narcotic, Australia, Drug Overdose, Female, Humans, Intensive Care Units, Liver Failure, Acute, Liver Transplantation, Mental Disorders, New Zealand, Treatment Outcome, Young Adult},\n\tpages = {188--199},\n}\n\n

\n

\n\n\n

\n OBJECTIVE: Acute liver failure (ALF) leads to severe illness and usually requires admission to the intensive care unit (ICU). Despite its importance, little is known about patients with ALF in Australia and New Zealand. DESIGN: Binational observational study to evaluate the aetiology, baseline characteristics, patterns of illness, management, and outcomes for patients with ALF admitted to Australian and New Zealand ICUs. SETTING: All six Australian and New Zealand ICUs in liver transplant centres submitted de-identified data for ten or more consecutive patients with ALF. Data were obtained from the clinical record and included baseline characteristics, aetiology, mode of presentation, illness severity, markers of liver failure, critical care interventions, utilisation of transplantation, and hospital outcome. RESULTS: We studied 62 patients with ALF. Paracetamol overdose (POD) was the underlying cause of ALF in 53% of patients (33/62), with staggered ingestion in 42% of patients (14/33). Among patients with POD, 70% (23/33) were young women, most had psychiatric diagnoses, and most presented relatively early with overt liver failure. This group were transplanted in only 6% of cases (2/33) and had an overall mortality of 24% (8/33). The remaining patients with ALF had less common conditions, such as hepatitis B and non-paracetamol drug-induced ALF. These patients presented later and exhibited less extreme evidence of acute hepatic necrosis. Transplantation was performed in 38% of patients (11/29) in this subgroup. The mortality of nontransplanted non-POD patients was 56% (10/18). Illness severity at ICU admission, initial requirement for organ support therapies and length of hospital stay were similar between patients with POD and non-POD ALF. CONCLUSION: POD is the major cause of ALF in Australian and New Zealand liver transplant centres and is a unique and separate form of ALF. It has a much lower associated mortality and treatment with liver transplantation than non-POD ALF. Non-POD patients have a poor prognosis in the absence of transplantation.\n

\n\n\n

\n \n\n \n \n \n \n \n \n Study protocol: NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC trial): a randomised controlled trial.\n \n \n \n \n\n\n \n Schlapbach, L. J; Horton, S. B.; Long, D. A.; Beca, J.; Erickson, S.; Festa, M.; d’Udekem , Y.; Alphonso, N.; Winlaw, D.; Johnson, K.; Delzoppo, C.; van Loon, K.; Gannon, B; Fooken, J.; Blumenthal, A.; Young, P.; Jones, M.; Butt, W.; and Schibler, A.\n\n\n \n\n\n\n BMJ Open, 9(8): e026664. August 2019.\n Number: 8\n\n\n\n
\n\n\n\n \n \n $\"Study$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{schlapbach_study_2019,\n\ttitle = {Study protocol: {NITric} oxide during cardiopulmonary bypass to improve {Recovery} in {Infants} with {Congenital} heart defects ({NITRIC} trial): a randomised controlled trial},\n\tvolume = {9},\n\tissn = {2044-6055, 2044-6055},\n\tshorttitle = {Study protocol},\n\turl = {http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-026664},\n\tdoi = {10.1136/bmjopen-2018-026664},\n\tabstract = {Introduction\n              Congenital heart disease (CHD) is a major cause of infant mortality. Many infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass (CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syndrome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and improved recovery. We hypothesised that using NO during CPB increases ventilator-free days (VFD) (the number of days patients spend alive and free from invasive mechanical ventilation up until day 28) compared with standard care. Here, we describe the NITRIC trial protocol.\n            \n            \n              Methods and analysis\n              The NITRIC trial is a randomised, double-blind, controlled, parallel-group, two-sided superiority trial to be conducted in six paediatric cardiac surgical centres. One thousand three-hundred and twenty infants {\\textless}2 years of age undergoing cardiac surgery with CPB will be randomly assigned to NO at 20 ppm administered into the CPB oxygenator for the duration of CPB or standard care (no NO) in a 1:1 ratio with stratification by age ({\\textless}6 and ≥6 weeks), single ventricle physiology (Y/N) and study centre. The primary outcome will be VFD to day 28. Secondary outcomes include a composite of LCOS, need for extracorporeal membrane oxygenation or death within 28 days of surgery; length of stay in intensive care and in hospital; and, healthcare costs. Analyses will be conducted on an intention-to-treat basis. Preplanned secondary analyses will investigate the impact of NO on host inflammatory profiles postsurgery.\n            \n            \n              Ethics and dissemination\n              The study has ethical approval (HREC/17/QRCH/43, dated 26 April 2017), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12617000821392) and commenced recruitment in July 2017. The primary manuscript will be submitted for publication in a peer-reviewed journal.\n            \n            \n              Trial registration number\n              ACTRN12617000821392},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2020-08-23},\n\tjournal = {BMJ Open},\n\tauthor = {Schlapbach, Luregn J and Horton, Stephen Brian and Long, Debbie Amanda and Beca, John and Erickson, Simon and Festa, Marino and d’Udekem, Yves and Alphonso, Nelson and Winlaw, David and Johnson, Kerry and Delzoppo, Carmel and van Loon, Kim and Gannon, B and Fooken, Jonas and Blumenthal, Antje and Young, Paul and Jones, Mark and Butt, Warwick and Schibler, Andreas},\n\tmonth = aug,\n\tyear = {2019},\n\tnote = {Number: 8},\n\tpages = {e026664},\n}\n\n

\n

\n\n\n

\n Introduction Congenital heart disease (CHD) is a major cause of infant mortality. Many infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass (CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syndrome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and improved recovery. We hypothesised that using NO during CPB increases ventilator-free days (VFD) (the number of days patients spend alive and free from invasive mechanical ventilation up until day 28) compared with standard care. Here, we describe the NITRIC trial protocol. Methods and analysis The NITRIC trial is a randomised, double-blind, controlled, parallel-group, two-sided superiority trial to be conducted in six paediatric cardiac surgical centres. One thousand three-hundred and twenty infants \\textless2 years of age undergoing cardiac surgery with CPB will be randomly assigned to NO at 20 ppm administered into the CPB oxygenator for the duration of CPB or standard care (no NO) in a 1:1 ratio with stratification by age (\\textless6 and ≥6 weeks), single ventricle physiology (Y/N) and study centre. The primary outcome will be VFD to day 28. Secondary outcomes include a composite of LCOS, need for extracorporeal membrane oxygenation or death within 28 days of surgery; length of stay in intensive care and in hospital; and, healthcare costs. Analyses will be conducted on an intention-to-treat basis. Preplanned secondary analyses will investigate the impact of NO on host inflammatory profiles postsurgery. Ethics and dissemination The study has ethical approval (HREC/17/QRCH/43, dated 26 April 2017), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12617000821392) and commenced recruitment in July 2017. The primary manuscript will be submitted for publication in a peer-reviewed journal. Trial registration number ACTRN12617000821392\n

\n\n\n

\n \n\n \n \n \n \n \n \n A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients.\n \n \n \n \n\n\n \n Weinkove, R.; Bowden, E.; Wood, C.; Campion, V.; Carter, J.; Hall, R.; Weatherall, M.; Beasley, R.; and Young, P.\n\n\n \n\n\n\n Leukemia & Lymphoma, 60(6): 1540–1547. May 2019.\n Number: 6\n\n\n\n
\n\n\n\n \n \n $\"A$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{weinkove_randomized_2019,\n\ttitle = {A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients},\n\tvolume = {60},\n\tissn = {1042-8194, 1029-2403},\n\turl = {https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1538512},\n\tdoi = {10.1080/10428194.2018.1538512},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2020-08-23},\n\tjournal = {Leukemia \\& Lymphoma},\n\tauthor = {Weinkove, Robert and Bowden, Emily and Wood, Catherine and Campion, Victoria and Carter, John and Hall, Richard and Weatherall, Mark and Beasley, Richard and Young, Paul},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 6},\n\tpages = {1540--1547},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n The learning health system: trial design and participant consent in comparative effectiveness research.\n \n \n \n \n\n\n \n Webster, M.; Stewart, R.; Aagaard, N.; and McArthur, C.\n\n\n \n\n\n\n European Heart Journal, 40(15): 1236–1240. April 2019.\n Number: 15\n\n\n\n
\n\n\n\n \n \n $\"The$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{webster_learning_2019,\n\ttitle = {The learning health system: trial design and participant consent in comparative effectiveness research},\n\tvolume = {40},\n\tissn = {0195-668X, 1522-9645},\n\tshorttitle = {The learning health system},\n\turl = {https://academic.oup.com/eurheartj/article/40/15/1236/4982605},\n\tdoi = {10.1093/eurheartj/ehy235},\n\tlanguage = {en},\n\tnumber = {15},\n\turldate = {2020-08-23},\n\tjournal = {European Heart Journal},\n\tauthor = {Webster, Mark and Stewart, Ralph and Aagaard, Nic and McArthur, Colin},\n\tmonth = apr,\n\tyear = {2019},\n\tnote = {Number: 15},\n\tpages = {1236--1240},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Characteristics and outcomes of patients with acute liver failure admitted to Australian and New Zealand intensive care units.\n \n \n \n \n\n\n \n Warrillow, S.; Bailey, M.; Pilcher, D.; Kazemi, A.; McArthur, C.; Young, P.; and Bellomo, R.\n\n\n \n\n\n\n Internal Medicine Journal, 49(7): 874–885. July 2019.\n Number: 7\n\n\n\n
\n\n\n\n \n \n $\"Characteristics$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{warrillow_characteristics_2019-1,\n\ttitle = {Characteristics and outcomes of patients with acute liver failure admitted to {Australian} and {New} {Zealand} intensive care units},\n\tvolume = {49},\n\tissn = {1444-0903, 1445-5994},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/imj.14167},\n\tdoi = {10.1111/imj.14167},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2020-08-23},\n\tjournal = {Internal Medicine Journal},\n\tauthor = {Warrillow, Stephen and Bailey, Michael and Pilcher, David and Kazemi, Alex and McArthur, Colin and Young, Paul and Bellomo, Rinaldo},\n\tmonth = jul,\n\tyear = {2019},\n\tnote = {Number: 7},\n\tpages = {874--885},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Chemical and physical variations of cannabis smoke from a variety of cannabis samples in New Zealand.\n \n \n \n \n\n\n \n Sheehan, T. J.; Hamnett, H. J.; Beasley, R.; and Fitzmaurice, P. S.\n\n\n \n\n\n\n Forensic Sciences Research, 4(2): 168–178. April 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n \n $\"Chemical$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{sheehan_chemical_2019,\n\ttitle = {Chemical and physical variations of cannabis smoke from a variety of cannabis samples in {New} {Zealand}},\n\tvolume = {4},\n\tissn = {2096-1790, 2471-1411},\n\turl = {https://www.tandfonline.com/doi/full/10.1080/20961790.2018.1445937},\n\tdoi = {10.1080/20961790.2018.1445937},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-08-23},\n\tjournal = {Forensic Sciences Research},\n\tauthor = {Sheehan, Thomas J. and Hamnett, Hilary J. and Beasley, Richard and Fitzmaurice, Paul S.},\n\tmonth = apr,\n\tyear = {2019},\n\tnote = {Number: 2},\n\tpages = {168--178},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Change in biomarkers of type-2 inflammation following severe exacerbations of asthma.\n \n \n \n \n\n\n \n Semprini, R.; Shortt, N.; Ebmeier, S.; Semprini, A.; Varughese, R.; Holweg, C. T J; Matthews, J. G; Fingleton, J.; Weatherall, M.; Beasley, R.; and Braithwaite, I.\n\n\n \n\n\n\n Thorax, 74(1): 95–98. January 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n $\"Change$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{semprini_change_2019,\n\ttitle = {Change in biomarkers of type-2 inflammation following severe exacerbations of asthma},\n\tvolume = {74},\n\tissn = {0040-6376, 1468-3296},\n\turl = {http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2018-211657},\n\tdoi = {10.1136/thoraxjnl-2018-211657},\n\tabstract = {We investigated the time course of change of type-2 asthma biomarkers after a severe asthma exacerbation. Blood eosinophils were lowest immediately after treatment was initiated (0.07 vs 0.33×10\n              9\n              /L, p{\\textless}0.001) while serum IgE levels were at their highest (339 vs 249 U/L, p{\\textless}0.001). Fractional exhaled Nitric Oxide levels were lowest 2 weeks after treatment (23 vs 33 ppb, p=0.06) and serum periostin levels were lowest 1 week after treatment (45·9 vs 50·9 ng/mL, p{\\textless}0.001). A delay of 4–8 weeks following a severe exacerbation is required if these biomarkers are used to guide the ongoing management of patients with asthma.\n            \n            \n              Trial registration number\n              Post-results; The Australia New Zealand Trial Registry, {\\textgreater}ACTRN12614000443695.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {Thorax},\n\tauthor = {Semprini, Ruth and Shortt, Nick and Ebmeier, Stefan and Semprini, Alex and Varughese, Rachel and Holweg, Cecile T J and Matthews, John G and Fingleton, James and Weatherall, Mark and Beasley, Richard and Braithwaite, Irene},\n\tmonth = jan,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {95--98},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n The Immunological Mysteries of Tuberculosis.\n \n \n \n \n\n\n \n Sabbagh, D. K.; Beasley, R.; and Marks, G. B.\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 7(2): 649–650. February 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n \n $\"The$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{sabbagh_immunological_2019,\n\ttitle = {The {Immunological} {Mysteries} of {Tuberculosis}},\n\tvolume = {7},\n\tissn = {22132198},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2213219818306688},\n\tdoi = {10.1016/j.jaip.2018.10.011},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-08-23},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Sabbagh, Doñah K. and Beasley, Richard and Marks, Guy B.},\n\tmonth = feb,\n\tyear = {2019},\n\tnote = {Number: 2},\n\tpages = {649--650},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n What Happens to Nutrition Intake in the Post-Intensive Care Unit Hospitalization Period? An Observational Cohort Study in Critically Ill Adults.\n \n \n \n \n\n\n \n Ridley, E. J.; Parke, R. L.; Davies, A. R.; Bailey, M.; Hodgson, C.; Deane, A. M.; McGuinness, S.; and Cooper, D. J.\n\n\n \n\n\n\n Journal of Parenteral and Enteral Nutrition, 43(1): 88–95. January 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n $\"What$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{ridley_what_2019,\n\ttitle = {What {Happens} to {Nutrition} {Intake} in the {Post}-{Intensive} {Care} {Unit} {Hospitalization} {Period}? {An} {Observational} {Cohort} {Study} in {Critically} {Ill} {Adults}},\n\tvolume = {43},\n\tissn = {01486071},\n\tshorttitle = {What {Happens} to {Nutrition} {Intake} in the {Post}-{Intensive} {Care} {Unit} {Hospitalization} {Period}?},\n\turl = {http://doi.wiley.com/10.1002/jpen.1196},\n\tdoi = {10.1002/jpen.1196},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Parenteral and Enteral Nutrition},\n\tauthor = {Ridley, Emma J. and Parke, Rachael L. and Davies, Andrew R. and Bailey, Michael and Hodgson, Carol and Deane, Adam M. and McGuinness, Shay and Cooper, D. James},\n\tmonth = jan,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {88--95},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Prospective observational study in patients with obstructive lung disease: NOVELTY design.\n \n \n \n \n\n\n \n Reddel, H. K.; Gerhardsson de Verdier, M.; Agustí, A.; Anderson, G.; Beasley, R.; Bel, E. H.; Janson, C.; Make, B.; Martin, R. J.; Pavord, I.; Price, D.; Keen, C.; Gardev, A.; Rennard, S.; Sveréus, A.; Bansal, A. T.; Brannman, L.; Karlsson, N.; Nuevo, J.; Nyberg, F.; Young, S. S.; and Vestbo, J.\n\n\n \n\n\n\n ERJ Open Research, 5(1): 00036–2018. February 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n $\"Prospective$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{reddel_prospective_2019,\n\ttitle = {Prospective observational study in patients with obstructive lung disease: {NOVELTY} design},\n\tvolume = {5},\n\tissn = {2312-0541},\n\tshorttitle = {Prospective observational study in patients with obstructive lung disease},\n\turl = {http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00036-2018},\n\tdoi = {10.1183/23120541.00036-2018},\n\tabstract = {Asthma and chronic obstructive pulmonary disease (COPD) have overlapping clinical features and share pathobiological mechanisms but are often considered distinct disorders. Prospective, observational studies across asthma, COPD and asthma–COPD overlap are limited. NOVELTY is a global, prospective observational 3-year study enrolling ∼12 000 patients ≥12 years of age from primary and specialist clinical practices in 19 countries (ClinicalTrials.gov identifier:\n              NCT02760329\n              ).\n            \n            NOVELTY's primary objectives are to describe patient characteristics, treatment patterns and disease burden over time, and to identify phenotypes and molecular endotypes associated with differential outcomes over time in patients with a diagnosis/suspected diagnosis of asthma and/or COPD. NOVELTY aims to recruit real-world patients, unlike clinical studies with restrictive inclusion/exclusion criteria.\n            \n              Data collected at yearly intervals include clinical assessments, spirometry, biospecimens, patient-reported outcomes (PROs) and healthcare utilisation (HCU). PROs and HCU will also be collected 3-monthly\n              via\n              internet/telephone. Data will be used to identify phenotypes and endotypes associated with different trajectories for symptom burden, clinical progression or remission and HCU. Results may allow patient classification across obstructive lung disease by clinical outcomes and biomarker profile, rather than by conventional diagnostic labels and severity categories.\n            \n            NOVELTY will provide a rich data source on obstructive lung disease, to help improve patient outcomes and aid novel drug development.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {ERJ Open Research},\n\tauthor = {Reddel, Helen K. and Gerhardsson de Verdier, Maria and Agustí, Alvar and Anderson, Gary and Beasley, Richard and Bel, Elisabeth H. and Janson, Christer and Make, Barry and Martin, Richard J. and Pavord, Ian and Price, David and Keen, Christina and Gardev, Asparuh and Rennard, Stephen and Sveréus, Alecka and Bansal, Aruna T. and Brannman, Lance and Karlsson, Niklas and Nuevo, Javier and Nyberg, Fredrik and Young, Simon S. and Vestbo, Jørgen},\n\tmonth = feb,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {00036--2018},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Early dysglycemia and mortality in traumatic brain injury and subarachnoid hemorrhage.\n \n \n \n \n\n\n \n Pappacena, S.; Bailey, M.; Cabrini, L.; Landoni, G.; Udy, A.; Pilcher, D. V.; Young, P.; and Bellomo, R.\n\n\n \n\n\n\n Minerva Anestesiologica, 85(8). July 2019.\n Number: 8\n\n\n\n
\n\n\n\n \n \n $\"Early$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{pappacena_early_2019,\n\ttitle = {Early dysglycemia and mortality in traumatic brain injury and subarachnoid hemorrhage},\n\tvolume = {85},\n\tissn = {03759393, 18271596},\n\turl = {https://www.minervamedica.it/index2.php?show=R02Y2019N08A0830},\n\tdoi = {10.23736/S0375-9393.19.13307-X},\n\tnumber = {8},\n\turldate = {2020-08-23},\n\tjournal = {Minerva Anestesiologica},\n\tauthor = {Pappacena, Simone and Bailey, Michael and Cabrini, Luca and Landoni, Giovanni and Udy, Andrew and Pilcher, David V. and Young, Paul and Bellomo, Rinaldo},\n\tmonth = jul,\n\tyear = {2019},\n\tnote = {Number: 8},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial.\n \n \n \n \n\n\n \n McKinstry, S.; Singer, J.; Baarsma, J. P.; Weatherall, M.; Beasley, R.; and Fingleton, J.\n\n\n \n\n\n\n Respirology, 24(11): 1081–1087. November 2019.\n Number: 11\n\n\n\n
\n\n\n\n \n \n $\"Nasal$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{mckinstry_nasal_2019,\n\ttitle = {Nasal high‐flow therapy compared with non‐invasive ventilation in {COPD} patients with chronic respiratory failure: {A} randomized controlled cross‐over trial},\n\tvolume = {24},\n\tissn = {1323-7799, 1440-1843},\n\tshorttitle = {Nasal high‐flow therapy compared with non‐invasive ventilation in {COPD} patients with chronic respiratory failure},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13575},\n\tdoi = {10.1111/resp.13575},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2020-08-23},\n\tjournal = {Respirology},\n\tauthor = {McKinstry, Steven and Singer, Joseph and Baarsma, Jan Pieter and Weatherall, Mark and Beasley, Richard and Fingleton, James},\n\tmonth = nov,\n\tyear = {2019},\n\tnote = {Number: 11},\n\tpages = {1081--1087},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report.\n \n \n \n \n\n\n \n McDonald, V. M.; Fingleton, J.; Agusti, A.; Hiles, S. A.; Clark, V. L.; Holland, A. E.; Marks, G. B.; Bardin, P. P.; Beasley, R.; Pavord, I. D.; Wark, P. A.; and Gibson, P. G.\n\n\n \n\n\n\n European Respiratory Journal, 53(5): 1802058. May 2019.\n Number: 5\n\n\n\n
\n\n\n\n \n \n $\"Treatable$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{mcdonald_treatable_2019,\n\ttitle = {Treatable traits: a new paradigm for 21st century management of chronic airway diseases: {Treatable} {Traits} {Down} {Under} {International} {Workshop} report},\n\tvolume = {53},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Treatable traits},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02058-2018},\n\tdoi = {10.1183/13993003.02058-2018},\n\tabstract = {“Treatable traits” have been proposed as a new paradigm for the management of airway diseases, particularly complex disease, which aims to apply personalised medicine to each individual to improve outcomes. Moving new treatment approaches from concepts to practice is challenging, but necessary. In an effort to accelerate progress in research and practice relating to the treatable traits approach, the Treatable Traits Down Under International Workshop was convened in Melbourne, Australia in May 2018. Here, we report the key concepts and research questions that emerged in discussions during the meeting. We propose a programme of research that involves gaining international consensus on candidate traits, recognising the prevalence of traits, and identifying a potential hierarchy of traits based on their clinical impact and responsiveness to treatment. We also reflect on research methods and designs that can generate new knowledge related to efficacy of the treatable traits approach and consider multidisciplinary models of care that may aid its implementation into practice.},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-08-23},\n\tjournal = {European Respiratory Journal},\n\tauthor = {McDonald, Vanessa M. and Fingleton, James and Agusti, Alvar and Hiles, Sarah A. and Clark, Vanessa L. and Holland, Anne E. and Marks, Guy B. and Bardin, Philip P. and Beasley, Richard and Pavord, Ian D. and Wark, Peter A.B. and Gibson, Peter G.},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 5},\n\tpages = {1802058},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Combined impact of healthy lifestyle factors on risk of asthma, rhinoconjunctivitis and eczema in school children: ISAAC phase III.\n \n \n \n \n\n\n \n Morales, E.; Strachan, D.; Asher, I.; Ellwood, P.; Pearce, N.; and Garcia-Marcos, L.\n\n\n \n\n\n\n Thorax, 74(6): 531–538. June 2019.\n Number: 6\n\n\n\n
\n\n\n\n \n \n $\"Combined$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{morales_combined_2019,\n\ttitle = {Combined impact of healthy lifestyle factors on risk of asthma, rhinoconjunctivitis and eczema in school children: {ISAAC} phase {III}},\n\tvolume = {74},\n\tissn = {0040-6376, 1468-3296},\n\tshorttitle = {Combined impact of healthy lifestyle factors on risk of asthma, rhinoconjunctivitis and eczema in school children},\n\turl = {http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2018-212668},\n\tdoi = {10.1136/thoraxjnl-2018-212668},\n\tabstract = {Background\n              Asthma is not the key focus of prevention strategies. A Healthy Lifestyle Index (HLI) was developed to examine the combined effect of modifiable lifestyle factors on asthma, rhinoconjunctivitis and eczema using data from the International Study of Asthma and Allergies in Childhood (ISAAC) phase III.\n            \n            \n              Methods\n              Information on symptoms of asthma, rhinoconjunctivitis, eczema and several lifestyle factors was obtained from children aged 6–7 years through written questionnaires. The HLI combined five lifestyle factors: no parental smoking, child’s adherence to Mediterranean diet, child’s healthy body mass index, high physical activity and non-sedentary behaviour. The association between the HLI and risk of asthma, rhinoconjunctivitis and eczema was evaluated using multilevel mixed-effects logistic regression models.\n            \n            \n              Findings\n              Data of 70 795 children from 37 centres in 19 countries were analysed. Each additional healthy lifestyle factor was associated with a reduced risk of current wheeze (OR 0.87, 95\\% CI 0.84 to 0.89), asthma ever (OR 0.89, 95\\% CI 0.87 to 0.92), current symptoms of rhinoconjunctivitis (OR 0.95, 95\\% CI 0.92 to 0.97) and current symptoms of eczema (OR 0.92, 95\\% CI 0.92 to 0.98). Theoretically, if associations were causal, a combination of four or five healthy lifestyle factors would result into a reduction up to 16\\% of asthma cases (ranging from 2.7\\% to 26.3 \\% according to region of the world).\n            \n            \n              Conclusions\n              These findings should be interpreted with caution given the limitations to infer causality from cross-sectional observational data. Efficacy of interventions to improve multiple modifiable lifestyle factors to reduce the burden asthma and allergy in childhood should be assessed.},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2020-08-23},\n\tjournal = {Thorax},\n\tauthor = {Morales, Eva and Strachan, David and Asher, Innes and Ellwood, Philippa and Pearce, Neil and Garcia-Marcos, Luis},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 6},\n\tpages = {531--538},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Trauma‐related admissions to intensive care units in Australia: the influence of Indigenous status on outcomes.\n \n \n \n \n\n\n \n Magee, F.; Wilson, A.; Bailey, M. J; Pilcher, D.; Secombe, P. J; Young, P.; and Bellomo, R.\n\n\n \n\n\n\n Medical Journal of Australia, 210(11): 493–498. June 2019.\n Number: 11\n\n\n\n
\n\n\n\n \n \n $\"Trauma‐related$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{magee_traumarelated_2019,\n\ttitle = {Trauma‐related admissions to intensive care units in {Australia}: the influence of {Indigenous} status on outcomes},\n\tvolume = {210},\n\tissn = {0025-729X, 1326-5377},\n\tshorttitle = {Trauma‐related admissions to intensive care units in {Australia}},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.5694/mja2.12028},\n\tdoi = {10.5694/mja2.12028},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2020-08-23},\n\tjournal = {Medical Journal of Australia},\n\tauthor = {Magee, Fraser and Wilson, Anthony and Bailey, Michael J and Pilcher, David and Secombe, Paul J and Young, Paul and Bellomo, Rinaldo},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 11},\n\tpages = {493--498},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Research nurses in New Zealand intensive care units: A qualitative descriptive study.\n \n \n \n \n\n\n \n Mackle, D.; and Nelson, K.\n\n\n \n\n\n\n Australian Critical Care, 32(2): 148–154. March 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n \n $\"Research$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{mackle_research_2019,\n\ttitle = {Research nurses in {New} {Zealand} intensive care units: {A} qualitative descriptive study},\n\tvolume = {32},\n\tissn = {10367314},\n\tshorttitle = {Research nurses in {New} {Zealand} intensive care units},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S1036731417303399},\n\tdoi = {10.1016/j.aucc.2018.03.005},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-08-23},\n\tjournal = {Australian Critical Care},\n\tauthor = {Mackle, Diane and Nelson, Katherine},\n\tmonth = mar,\n\tyear = {2019},\n\tnote = {Number: 2},\n\tpages = {148--154},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Development and Validation of a Score to Identify Cardiac Surgery Patients at High Risk of Prolonged Mechanical Ventilation.\n \n \n \n \n\n\n \n Hessels, L.; Coulson, T. G.; Seevanayagam, S.; Young, P.; Pilcher, D.; Marhoon, N.; and Bellomo, R.\n\n\n \n\n\n\n Journal of Cardiothoracic and Vascular Anesthesia, 33(10): 2709–2716. October 2019.\n Number: 10\n\n\n\n
\n\n\n\n \n \n $\"Development$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{hessels_development_2019,\n\ttitle = {Development and {Validation} of a {Score} to {Identify} {Cardiac} {Surgery} {Patients} at {High} {Risk} of {Prolonged} {Mechanical} {Ventilation}},\n\tvolume = {33},\n\tissn = {10530770},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S1053077019302691},\n\tdoi = {10.1053/j.jvca.2019.03.009},\n\tlanguage = {en},\n\tnumber = {10},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Cardiothoracic and Vascular Anesthesia},\n\tauthor = {Hessels, Lara and Coulson, Tim G. and Seevanayagam, Siven and Young, Paul and Pilcher, David and Marhoon, Nada and Bellomo, Rinaldo},\n\tmonth = oct,\n\tyear = {2019},\n\tnote = {Number: 10},\n\tpages = {2709--2716},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.\n \n \n \n \n\n\n \n Hardy, J.; Baggott, C.; Fingleton, J.; Reddel, H. K; Hancox, R. J; Harwood, M.; Corin, A.; Sparks, J.; Hall, D.; Sabbagh, D.; Mane, S.; Vohlidkova, A.; Martindale, J.; Williams, M.; Shirtcliffe, P.; Holliday, M.; Weatherall, M.; Beasley, R.; Corin, A.; Dronfield, L.; Helm, C.; Paterson, T.; Poudel, B.; Dyer, M.; Jasinski, C.; Sheahan, D.; Sheahan, P.; Gailer, N.; Van Zuilen, J.; Basa, A.; Devereaux, C.; Egan, K.; Haughey, S.; Marks, R.; Venter, D.; Zhang, H.; Trevithick, K.; Williams, M.; Williams, P.; Baggott, C.; Beasley, R.; Braithwaite, I.; Eathorne, A.; Ebmeier, S.; Fingleton, J.; Hall, D.; Hardy, J.; Harwood, M.; Holliday, M.; Houghton, C.; Mane, S.; Martindale, J.; Oldfield, K.; Pilcher, J.; Sabbagh, D.; Shirtcliffe, P.; Snively, S.; Sparks, J.; Vohlidkova, A.; Williams, M.; Collins, P.; Hassan, S.; Lam, A.; Lionnet, C.; Montgomery, B.; Smaill, L.; Moon, S.; Quinn, D.; Bayly-McCredie, E.; Millar-Coote, C.; Millar-Coote, D.; Reid, J.; Samuel, A.; Burton, N.; Mullard, T.; Tranquilino, T.; Watson, E.; Bell, J.; Harris, R.; Richmond, J.; Smith, S.; Krivan, B.; Robertson, C.; Hancox, R. J; Weatherall, M.; Glensor, S.; O'Connor, D.; Porrachia, A.; and Reddel, H. K\n\n\n \n\n\n\n The Lancet, 394(10202): 919–928. September 2019.\n Number: 10202\n\n\n\n
\n\n\n\n \n \n $\"Budesonide-formoterol$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{hardy_budesonide-formoterol_2019,\n\ttitle = {Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma ({PRACTICAL}): a 52-week, open-label, multicentre, superiority, randomised controlled trial},\n\tvolume = {394},\n\tissn = {01406736},\n\tshorttitle = {Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma ({PRACTICAL})},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0140673619319488},\n\tdoi = {10.1016/S0140-6736(19)31948-8},\n\tlanguage = {en},\n\tnumber = {10202},\n\turldate = {2020-08-23},\n\tjournal = {The Lancet},\n\tauthor = {Hardy, Jo and Baggott, Christina and Fingleton, James and Reddel, Helen K and Hancox, Robert J and Harwood, Matire and Corin, Andrew and Sparks, Jenny and Hall, Daniela and Sabbagh, Doñah and Mane, Saras and Vohlidkova, Alexandra and Martindale, John and Williams, Mathew and Shirtcliffe, Philippa and Holliday, Mark and Weatherall, Mark and Beasley, Richard and Corin, Andrew and Dronfield, Liz and Helm, Colin and Paterson, Tracy and Poudel, Bhuwan and Dyer, Malcolm and Jasinski, Christine and Sheahan, Davitt and Sheahan, Pamela and Gailer, Nick and Van Zuilen, Jan and Basa, Andy and Devereaux, Christine and Egan, Karin and Haughey, Sneha and Marks, Rodney and Venter, Dirk and Zhang, Hank and Trevithick, Karen and Williams, Mike and Williams, Philippa and Baggott, Christina and Beasley, Richard and Braithwaite, Irene and Eathorne, Alexandra and Ebmeier, Stefan and Fingleton, James and Hall, Daniela and Hardy, Jo and Harwood, Matire and Holliday, Mark and Houghton, Claire and Mane, Saras and Martindale, John and Oldfield, Karen and Pilcher, Janine and Sabbagh, Doñah and Shirtcliffe, Philippa and Snively, Suzanne and Sparks, Jenny and Vohlidkova, Alexandra and Williams, Mathew and Collins, Patrick and Hassan, Summer and Lam, Annika and Lionnet, Claudette and Montgomery, Barney and Smaill, Liz and Moon, Stella and Quinn, Dean and Bayly-McCredie, Elena and Millar-Coote, Chris and Millar-Coote, Dean and Reid, Jim and Samuel, Anna and Burton, Nicola and Mullard, Tina and Tranquilino, Tyronne and Watson, Edward and Bell, Jill and Harris, Rachel and Richmond, John and Smith, Sue and Krivan, Brent and Robertson, Cheryl and Hancox, Robert J and Weatherall, Mark and Glensor, Sue and O'Connor, Dermot and Porrachia, Anne-Christine and Reddel, Helen K},\n\tmonth = sep,\n\tyear = {2019},\n\tnote = {Number: 10202},\n\tpages = {919--928},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Why do multicenter randomized controlled trials not confirm the positive findings of single center randomized controlled trials in acute care?.\n \n \n \n \n\n\n \n Landoni, G.; Pieri, M.; Young, P. J.; and Bellomo, R.\n\n\n \n\n\n\n Minerva Anestesiologica, 85(2). February 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n \n $\"Why$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{landoni_why_2019,\n\ttitle = {Why do multicenter randomized controlled trials not confirm the positive findings of single center randomized controlled trials in acute care?},\n\tvolume = {85},\n\tissn = {03759393, 18271596},\n\turl = {https://www.minervamedica.it/index2.php?show=R02Y2019N02A0194},\n\tdoi = {10.23736/S0375-9393.18.13070-7},\n\tnumber = {2},\n\turldate = {2020-08-23},\n\tjournal = {Minerva Anestesiologica},\n\tauthor = {Landoni, Giovanni and Pieri, Marina and Young, Paul J. and Bellomo, Rinaldo},\n\tmonth = feb,\n\tyear = {2019},\n\tnote = {Number: 2},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Vitamin C, Hydrocortisone and Thiamine in Patients with Septic Shock (VITAMINS) trial: study protocol and statistical analysis plan.\n \n \n \n\n\n \n Fujii, T.; Udy, A. A.; Deane, A. M.; Luethi, N.; Bailey, M.; Eastwood, G. M.; Frei, D.; French, C.; Orford, N.; Shehabi, Y.; Young, P. J.; Bellomo, R.; and VITAMINS trial investigators\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 21(2): 119–125. June 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{fujii_vitamin_2019,\n\ttitle = {Vitamin {C}, {Hydrocortisone} and {Thiamine} in {Patients} with {Septic} {Shock} ({VITAMINS}) trial: study protocol and statistical analysis plan},\n\tvolume = {21},\n\tissn = {1441-2772},\n\tshorttitle = {Vitamin {C}, {Hydrocortisone} and {Thiamine} in {Patients} with {Septic} {Shock} ({VITAMINS}) trial},\n\tabstract = {BACKGROUND: Septic shock is associated with poor outcomes. Vitamin C (ascorbic acid) is a cellular antioxidant and has anti-inflammatory properties. Whether the combination therapy of vitamin C, thiamine and hydrocortisone reduces vasopressor dependency in septic shock is unclear.\nOBJECTIVES: To describe the protocol and statistical analysis plan of a multicentre, open-label, prospective, phase 2 randomised clinical trial evaluating the effects of vitamin C, thiamine and hydrocortisone when compared with hydrocortisone monotherapy on the duration of vasopressor administration in critically ill patients with septic shock.\nMETHODS: VITAMINS is a multicentre cardiovascular efficacy trial in adult patients with septic shock. Randomisation occurs via a secure website with stratification by site, and allocation concealment is maintained throughout the trial. The primary outcome is the duration of time alive and free of vasopressor administration at Day 7. Secondary outcomes include feasibility endpoints and some patientcentred outcomes. All analyses will be conducted on an intention-to-treat basis.\nCONCLUSION: The VITAMINS trial will determine whether combination therapy of vitamin C, thiamine and hydrocortisone when compared with hydrocortisone increases vasopressor-free hours in critically ill patients with septic shock. The conduct of this study will provide important information on the feasibility of studying this intervention in a phase 3 trial.\nTRIAL REGISTRATION: ClinicalTrials.gov, identification No. NCT03333278.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Fujii, Tomoko and Udy, Andrew A. and Deane, Adam M. and Luethi, Nora and Bailey, Michael and Eastwood, Glenn M. and Frei, Daniel and French, Craig and Orford, Neil and Shehabi, Yahya and Young, Paul J. and Bellomo, Rinaldo and {VITAMINS trial investigators}},\n\tmonth = jun,\n\tyear = {2019},\n\tpmid = {31142242},\n\tnote = {Number: 2},\n\tkeywords = {Adult, Ascorbic Acid, Drug Therapy, Combination, Female, Hospital Mortality, Humans, Hydrocortisone, Intensive Care Units, Male, Prospective Studies, Shock, Septic, Thiamine, Treatment Outcome, Vasoconstrictor Agents, Vitamins},\n\tpages = {119--125},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2): A randomized clinical trial—Rationale and design.\n \n \n \n \n\n\n \n Dankiewicz, J.; Cronberg, T.; Lilja, G.; Jakobsen, J. C.; Bělohlávek, J.; Callaway, C.; Cariou, A.; Eastwood, G.; Erlinge, D.; Hovdenes, J.; Joannidis, M.; Kirkegaard, H.; Kuiper, M.; Levin, H.; Morgan, M. P.; Nichol, A. D; Nordberg, P.; Oddo, M.; Pelosi, P.; Rylander, C.; Saxena, M.; Storm, C.; Taccone, F.; Ullén, S.; Wise, M. P.; Young, P.; Friberg, H.; and Nielsen, N.\n\n\n \n\n\n\n American Heart Journal, 217: 23–31. November 2019.\n \n\n\n\n
\n\n\n\n \n \n $\"Targeted$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{dankiewicz_targeted_2019,\n\ttitle = {Targeted hypothermia versus targeted {Normothermia} after out-of-hospital cardiac arrest ({TTM2}): {A} randomized clinical trial—{Rationale} and design},\n\tvolume = {217},\n\tissn = {00028703},\n\tshorttitle = {Targeted hypothermia versus targeted {Normothermia} after out-of-hospital cardiac arrest ({TTM2})},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0002870319301577},\n\tdoi = {10.1016/j.ahj.2019.06.012},\n\tlanguage = {en},\n\turldate = {2020-08-23},\n\tjournal = {American Heart Journal},\n\tauthor = {Dankiewicz, Josef and Cronberg, Tobias and Lilja, Gisela and Jakobsen, Janus Christian and Bělohlávek, Jan and Callaway, Clifton and Cariou, Alain and Eastwood, Glenn and Erlinge, David and Hovdenes, Jan and Joannidis, Michael and Kirkegaard, Hans and Kuiper, Michael and Levin, Helena and Morgan, Matt P.G. and Nichol, Alistair D and Nordberg, Per and Oddo, Mauro and Pelosi, Paolo and Rylander, Christian and Saxena, Manoj and Storm, Christian and Taccone, Fabio and Ullén, Susann and Wise, Matthew P. and Young, Paul and Friberg, Hans and Nielsen, Niklas},\n\tmonth = nov,\n\tyear = {2019},\n\tpages = {23--31},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Accuracy and precision of transcutaneous carbon dioxide monitoring: a systematic review and meta-analysis.\n \n \n \n \n\n\n \n Conway, A.; Tipton, E.; Liu, W.; Conway, Z.; Soalheira, K.; Sutherland, J.; and Fingleton, J.\n\n\n \n\n\n\n Thorax, 74(2): 157–163. February 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n \n $\"Accuracy$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{conway_accuracy_2019,\n\ttitle = {Accuracy and precision of transcutaneous carbon dioxide monitoring: a systematic review and meta-analysis},\n\tvolume = {74},\n\tissn = {0040-6376, 1468-3296},\n\tshorttitle = {Accuracy and precision of transcutaneous carbon dioxide monitoring},\n\turl = {http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2017-211466},\n\tdoi = {10.1136/thoraxjnl-2017-211466},\n\tabstract = {Background\n              \n                Transcutaneous carbon dioxide (TcCO\n                2\n                ) monitoring is a non-invasive alternative to arterial blood sampling. The aim of this review was to determine the accuracy and precision of TcCO\n                2\n                measurements.\n              \n            \n            \n              Methods\n              \n                Medline and EMBASE (2000–2016) were searched for studies that reported on a measurement of PaCO\n                2\n                that coincided with a measurement of TcCO\n                2\n                . Study selection and quality assessment (using the revised Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2)) were performed independently. The Grading Quality of Evidence and Strength of Recommendation approach was used to summarise the strength of the body of evidence. Pooled estimates of the mean bias between TcCO\n                2\n                and PaCO\n                2\n                and limits of agreement with outer 95\\% CIs (termed population limits of agreement) were calculated.\n              \n            \n            \n              Results\n              \n                The mean bias was −0.1 mm Hg and the population limits of agreement were −15 to 15 mm Hg for 7021 paired measurements taken from 2817 participants in 73 studies, which was outside of the clinically acceptable range (7.5 mm Hg). The lowest PaCO\n                2\n                reported in the studies was 18 mm Hg and the highest was 103 mm Hg. The major sources of inconsistency were sensor location and temperature. The population limits of agreement were within the clinically acceptable range across 3974 paired measurements from 1786 participants in 44 studies that applied the sensor to the earlobe using the TOSCA and Sentec devices (−6 to 6 mm Hg).\n              \n            \n            \n              Conclusion\n              \n                There are substantial differences between TcCO\n                2\n                and PaCO\n                2\n                depending on the context in which this technology is used. TcCO\n                2\n                sensors should preferentially be applied to the earlobe and users should consider setting the temperature of the sensor higher than 42°C when monitoring at other sites.\n              \n            \n            \n              Systematic review registration number\n              PROSPERO; CRD42017057450.},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-08-23},\n\tjournal = {Thorax},\n\tauthor = {Conway, Aaron and Tipton, Elizabeth and Liu, Wei-Hong and Conway, Zachary and Soalheira, Kathleen and Sutherland, Joanna and Fingleton, James},\n\tmonth = feb,\n\tyear = {2019},\n\tnote = {Number: 2},\n\tpages = {157--163},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Sequence analysis of capnography waveform abnormalities during nurse-administered procedural sedation and analgesia in the cardiac catheterization laboratory.\n \n \n \n \n\n\n \n Conway, A.; Collins, P.; Chang, K.; Mafeld, S.; Sutherland, J.; and Fingleton, J.\n\n\n \n\n\n\n Scientific Reports, 9(1): 10214. December 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n $\"Sequence$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{conway_sequence_2019,\n\ttitle = {Sequence analysis of capnography waveform abnormalities during nurse-administered procedural sedation and analgesia in the cardiac catheterization laboratory},\n\tvolume = {9},\n\tissn = {2045-2322},\n\turl = {http://www.nature.com/articles/s41598-019-46751-2},\n\tdoi = {10.1038/s41598-019-46751-2},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {Scientific Reports},\n\tauthor = {Conway, Aaron and Collins, Peter and Chang, Kristina and Mafeld, Sebastian and Sutherland, Joanna and Fingleton, James},\n\tmonth = dec,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {10214},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Study protocol: A randomized controlled trial assessing the avoidance of endotracheal suction in cardiac surgical patients ventilated for ≤ 12 hr.\n \n \n \n \n\n\n \n Gilder, E.; Parke, R. L.; McGuinness, S.; and Jull, A.\n\n\n \n\n\n\n Journal of Advanced Nursing, 75(9): 2006–2014. September 2019.\n Number: 9\n\n\n\n
\n\n\n\n \n \n $\"Study$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{gilder_study_2019,\n\ttitle = {Study protocol: {A} randomized controlled trial assessing the avoidance of endotracheal suction in cardiac surgical patients ventilated for ≤ 12 hr},\n\tvolume = {75},\n\tissn = {0309-2402, 1365-2648},\n\tshorttitle = {Study protocol},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/jan.13994},\n\tdoi = {10.1111/jan.13994},\n\tlanguage = {en},\n\tnumber = {9},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Advanced Nursing},\n\tauthor = {Gilder, Eileen and Parke, Rachael L. and McGuinness, Shay and Jull, Andrew},\n\tmonth = sep,\n\tyear = {2019},\n\tnote = {Number: 9},\n\tpages = {2006--2014},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Vitamin C therapy for patients with sepsis or septic shock: a protocol for a systematic review and a network meta-analysis.\n \n \n \n\n\n \n Fujii, T.; Belletti, A.; Carr, A.; Furukawa, T. A.; Luethi, N.; Putzu, A.; Sartini, C.; Salanti, G.; Tsujimoto, Y.; Udy, A. A.; Young, P. J.; and Bellomo, R.\n\n\n \n\n\n\n BMJ open, 9(11): e033458. 2019.\n Number: 11\n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{fujii_vitamin_2019-1,\n\ttitle = {Vitamin {C} therapy for patients with sepsis or septic shock: a protocol for a systematic review and a network meta-analysis},\n\tvolume = {9},\n\tissn = {2044-6055},\n\tshorttitle = {Vitamin {C} therapy for patients with sepsis or septic shock},\n\tdoi = {10.1136/bmjopen-2019-033458},\n\tabstract = {INTRODUCTION: Vasoplegia is common and associated with a poor prognosis in patients with sepsis and septic shock. Vitamin C therapy in combination with vitamin B1 and glucocorticoid, as well as monotherapy in various doses, has been investigated as a treatment for the vasoplegic state in sepsis, through targeting the inflammatory cascade. However, the combination effect and the relative contribution of each drug have not been well evaluated. Furthermore, the best combination between the three agents is currently unknown. We are planning a systematic review (SR) with network meta-analysis (NMA) to compare the different treatments and identify the combination with the most favourable effect on survival.\nMETHODS AND ANALYSIS: We will include all randomised controlled trials comparing any intervention using intravenous vitamin C, vitamin B1 and/or glucocorticoid with another or with placebo in the treatment of sepsis. We are interested in comparing the following active interventions. Very high-dose vitamin C (≥12 g/day), high-dose vitamin C (≥6 g/day), vitamin C ({\\textless}6 g/day); low-dose glucocorticoid ({\\textless}400 mg/day of hydrocortisone (or equivalent)), vitamin B1 and combinations of the drugs above. The primary outcome will be all-cause mortality at the longest follow-up within 1 year but 90 days or longer postrandomisation. All relevant studies will be sought through database searches and trial registries. All reference selection and data extraction will be conducted by two independent reviewers. We will conduct a random-effects NMA to synthesise all evidence for each outcome and obtain a comprehensive ranking of all treatments. We will use the surface under the cumulative ranking curve and the mean ranks to rank the various interventions. To differentiate between the effect of combination therapies and the effect of a component, we will employ a component NMA.\nETHICS AND DISSEMINATION: This SR does not require ethical approval. We will publish findings from this systematic review in a peer-reviewed scientific journal and present these at scientific conferences.\nPROSPERO REGISTRATION NUMBER: CRD42018103860.},\n\tlanguage = {eng},\n\tnumber = {11},\n\tjournal = {BMJ open},\n\tauthor = {Fujii, Tomoko and Belletti, Alessandro and Carr, Anitra and Furukawa, Toshi A. and Luethi, Nora and Putzu, Alessandro and Sartini, Chiara and Salanti, Georgia and Tsujimoto, Yasushi and Udy, Andrew A. and Young, Paul J. and Bellomo, Rinaldo},\n\tyear = {2019},\n\tpmid = {31722954},\n\tpmcid = {PMC6858173},\n\tnote = {Number: 11},\n\tkeywords = {adult intensive \\& critical care, clinical trials, statistics \\& research methods},\n\tpages = {e033458},\n}\n\n

\n

\n\n\n

\n INTRODUCTION: Vasoplegia is common and associated with a poor prognosis in patients with sepsis and septic shock. Vitamin C therapy in combination with vitamin B1 and glucocorticoid, as well as monotherapy in various doses, has been investigated as a treatment for the vasoplegic state in sepsis, through targeting the inflammatory cascade. However, the combination effect and the relative contribution of each drug have not been well evaluated. Furthermore, the best combination between the three agents is currently unknown. We are planning a systematic review (SR) with network meta-analysis (NMA) to compare the different treatments and identify the combination with the most favourable effect on survival. METHODS AND ANALYSIS: We will include all randomised controlled trials comparing any intervention using intravenous vitamin C, vitamin B1 and/or glucocorticoid with another or with placebo in the treatment of sepsis. We are interested in comparing the following active interventions. Very high-dose vitamin C (≥12 g/day), high-dose vitamin C (≥6 g/day), vitamin C (\\textless6 g/day); low-dose glucocorticoid (\\textless400 mg/day of hydrocortisone (or equivalent)), vitamin B1 and combinations of the drugs above. The primary outcome will be all-cause mortality at the longest follow-up within 1 year but 90 days or longer postrandomisation. All relevant studies will be sought through database searches and trial registries. All reference selection and data extraction will be conducted by two independent reviewers. We will conduct a random-effects NMA to synthesise all evidence for each outcome and obtain a comprehensive ranking of all treatments. We will use the surface under the cumulative ranking curve and the mean ranks to rank the various interventions. To differentiate between the effect of combination therapies and the effect of a component, we will employ a component NMA. ETHICS AND DISSEMINATION: This SR does not require ethical approval. We will publish findings from this systematic review in a peer-reviewed scientific journal and present these at scientific conferences. PROSPERO REGISTRATION NUMBER: CRD42018103860.\n

\n\n\n

\n \n\n \n \n \n \n \n \n Practice patterns and perceptions of Australian and New Zealand anaesthetists towards perioperative oxygen therapy.\n \n \n \n \n\n\n \n Frei, D. R; Beasley, R.; Campbell, D.; Leslie, K.; Merry, A. F; Moore, M.; Myles, P. S; Ruawai-Hamilton, L.; Short, T. G; and Young, P. J\n\n\n \n\n\n\n Anaesthesia and Intensive Care, 47(3): 288–294. May 2019.\n Number: 3\n\n\n\n
\n\n\n\n \n \n $\"Practice$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{frei_practice_2019,\n\ttitle = {Practice patterns and perceptions of {Australian} and {New} {Zealand} anaesthetists towards perioperative oxygen therapy},\n\tvolume = {47},\n\tissn = {0310-057X, 1448-0271},\n\turl = {http://journals.sagepub.com/doi/10.1177/0310057X19842245},\n\tdoi = {10.1177/0310057X19842245},\n\tabstract = {We conducted a survey of Australian and New Zealand anaesthetists to determine self-reported practice of perioperative oxygen administration and to quantify perceptions regarding the perceived benefits and risks resulting from liberal oxygen therapy delivered in a manner consistent with the current World Health Organization guidelines. In addition, we sought feedback on the acceptability of several proposed clinical trial designs aiming to assess the overall effect of liberal and restricted perioperative oxygen regimens on patient outcomes. We developed a 23-question electronic survey that was emailed to 972 randomly selected Australian and New Zealand College of Anaesthetists (ANZCA) Fellows. We received responses from 282 of 972 invitees (response rate 29\\%). The majority of survey participants indicated that they routinely titrate inspired oxygen to a level they feel is safe (164/282, 58\\%) or minimise oxygen administration (82/282, 29\\%), while 5\\% of respondents indicated that they aim to maximise oxygen administration. The mean value for targeted intraoperative fraction inspired oxygen (FiO\n              2\n              ) was 0.41 (standard deviation 0.12). Of the survey respondents, 2/282 (0.7\\%) indicated they believe that routine intra- and postoperative administration of ≥80\\% oxygen reduces the risk of surgical site infection. Well-designed and conducted randomised trials on this topic may help to better direct clinicians' choices. A high level of willingness to participate (80\\% of responses) in a study designed to investigate the impact of differing approaches to perioperative oxygen administration suggests that recruitment is likely to be feasible in a future study.},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2020-08-23},\n\tjournal = {Anaesthesia and Intensive Care},\n\tauthor = {Frei, Daniel R and Beasley, Richard and Campbell, Douglas and Leslie, Kate and Merry, Alan F and Moore, Matthew and Myles, Paul S and Ruawai-Hamilton, Laura and Short, Tim G and Young, Paul J},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 3},\n\tpages = {288--294},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma.\n \n \n \n \n\n\n \n Denton, E.; Hore-Lacy, F.; Radhakrishna, N.; Gilbert, A.; Tay, T.; Lee, J.; Dabscheck, E.; Harvey, E. S.; Bulathsinhala, L.; Fingleton, J.; Price, D.; Gibson, P. G.; O'Hehir, R.; and Hew, M.\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 7(5): 1440–1449. May 2019.\n Number: 5\n\n\n\n
\n\n\n\n \n \n $\"Severe$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{denton_severe_2019,\n\ttitle = {Severe {Asthma} {Global} {Evaluation} ({SAGE}): {An} {Electronic} {Platform} for {Severe} {Asthma}},\n\tvolume = {7},\n\tissn = {22132198},\n\tshorttitle = {Severe {Asthma} {Global} {Evaluation} ({SAGE})},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S221321981930265X},\n\tdoi = {10.1016/j.jaip.2019.02.042},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-08-23},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Denton, Eve and Hore-Lacy, Fiona and Radhakrishna, Naghmeh and Gilbert, Annie and Tay, TunnRen and Lee, Joy and Dabscheck, Eli and Harvey, Erin S. and Bulathsinhala, Lakmini and Fingleton, James and Price, David and Gibson, Peter G. and O'Hehir, Robyn and Hew, Mark},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 5},\n\tpages = {1440--1449},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Pre-apneic capnography waveform abnormalities during procedural sedation and analgesia.\n \n \n \n \n\n\n \n Conway, A.; Collins, P.; Chang, K.; Mafeld, S.; Sutherland, J.; Fingleton, J.; and Parotto, M.\n\n\n \n\n\n\n Journal of Clinical Monitoring and Computing. September 2019.\n \n\n\n\n
\n\n\n\n \n \n $\"Pre-apneic$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{conway_pre-apneic_2019,\n\ttitle = {Pre-apneic capnography waveform abnormalities during procedural sedation and analgesia},\n\tissn = {1387-1307, 1573-2614},\n\turl = {http://link.springer.com/10.1007/s10877-019-00391-z},\n\tdoi = {10.1007/s10877-019-00391-z},\n\tlanguage = {en},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Clinical Monitoring and Computing},\n\tauthor = {Conway, Aaron and Collins, Peter and Chang, Kristina and Mafeld, Sebastian and Sutherland, Joanna and Fingleton, James and Parotto, Matteo},\n\tmonth = sep,\n\tyear = {2019},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n The efficacy of problem solving therapy to reduce post stroke emotional distress in younger (18-65) stroke survivors.\n \n \n \n\n\n \n Chalmers, C.; Leathem, J.; Bennett, S.; McNaughton, H.; and Mahawish, K.\n\n\n \n\n\n\n Disability and Rehabilitation, 41(7): 753–762. 2019.\n Number: 7\n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{chalmers_efficacy_2019,\n\ttitle = {The efficacy of problem solving therapy to reduce post stroke emotional distress in younger (18-65) stroke survivors},\n\tvolume = {41},\n\tissn = {1464-5165},\n\tdoi = {10.1080/09638288.2017.1408707},\n\tabstract = {PURPOSE: To investigate the efficacy of problem solving therapy for reducing the emotional distress experienced by younger stroke survivors.\nMETHOD: A non-randomized waitlist controlled design was used to compare outcome measures for the treatment group and a waitlist control group at baseline and post-waitlist/post-therapy. After the waitlist group received problem solving therapy an analysis was completed on the pooled outcome measures at baseline, post-treatment, and three-month follow-up.\nRESULTS: Changes on outcome measures between baseline and post-treatment (n = 13) were not significantly different between the two groups, treatment (n = 13), and the waitlist control group (n = 16) (between-subject design). The pooled data (n = 28) indicated that receiving problem solving therapy significantly reduced participants levels of depression and anxiety and increased quality of life levels from baseline to follow up (within-subject design), however, methodological limitations, such as the lack of a control group reduce the validity of this finding.\nCONCLUSION: The between-subject results suggest that there was no significant difference between those that received problem solving therapy and a waitlist control group between baseline and post-waitlist/post-therapy. The within-subject design suggests that problem solving therapy may be beneficial for younger stroke survivors when they are given some time to learn and implement the skills into their day to day life. However, additional research with a control group is required to investigate this further. This study provides limited evidence for the provision of support groups for younger stroke survivors post stroke, however, it remains unclear about what type of support this should be. Implications for Rehabilitation Problem solving therapy is no more effective for reducing post stroke distress than a wait-list control group. Problem solving therapy may be perceived as helpful and enjoyable by younger stroke survivors. Younger stroke survivors may use the skills learnt from problem solving therapy to solve problems in their day to day lives. Younger stroke survivors may benefit from age appropriate psychological support; however, future research is needed to determine what type of support this should be.},\n\tlanguage = {eng},\n\tnumber = {7},\n\tjournal = {Disability and Rehabilitation},\n\tauthor = {Chalmers, Charlotte and Leathem, Janet and Bennett, Simon and McNaughton, Harry and Mahawish, Karim},\n\tyear = {2019},\n\tpmid = {29172817},\n\tnote = {Number: 7},\n\tkeywords = {Adult, Anxiety, Depression, Female, Humans, Male, Middle Aged, Problem Solving, Psychological Distress, Psychosocial Support Systems, Psychotherapy, Quality of Life, Stroke, Stroke Rehabilitation, Survivors, anxiety, depression, perceived support, problem solving, therapy, younger people},\n\tpages = {753--762},\n}\n\n

\n

\n\n\n

\n PURPOSE: To investigate the efficacy of problem solving therapy for reducing the emotional distress experienced by younger stroke survivors. METHOD: A non-randomized waitlist controlled design was used to compare outcome measures for the treatment group and a waitlist control group at baseline and post-waitlist/post-therapy. After the waitlist group received problem solving therapy an analysis was completed on the pooled outcome measures at baseline, post-treatment, and three-month follow-up. RESULTS: Changes on outcome measures between baseline and post-treatment (n = 13) were not significantly different between the two groups, treatment (n = 13), and the waitlist control group (n = 16) (between-subject design). The pooled data (n = 28) indicated that receiving problem solving therapy significantly reduced participants levels of depression and anxiety and increased quality of life levels from baseline to follow up (within-subject design), however, methodological limitations, such as the lack of a control group reduce the validity of this finding. CONCLUSION: The between-subject results suggest that there was no significant difference between those that received problem solving therapy and a waitlist control group between baseline and post-waitlist/post-therapy. The within-subject design suggests that problem solving therapy may be beneficial for younger stroke survivors when they are given some time to learn and implement the skills into their day to day life. However, additional research with a control group is required to investigate this further. This study provides limited evidence for the provision of support groups for younger stroke survivors post stroke, however, it remains unclear about what type of support this should be. Implications for Rehabilitation Problem solving therapy is no more effective for reducing post stroke distress than a wait-list control group. Problem solving therapy may be perceived as helpful and enjoyable by younger stroke survivors. Younger stroke survivors may use the skills learnt from problem solving therapy to solve problems in their day to day lives. Younger stroke survivors may benefit from age appropriate psychological support; however, future research is needed to determine what type of support this should be.\n

\n\n\n

\n \n\n \n \n \n \n \n \n Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold.\n \n \n \n \n\n\n \n Bird, G.; Braithwaite, I.; Harper, J.; McKinstry, S.; Koorevaar, I.; Fingleton, J.; Semprini, A.; Dilcher, M.; Jennings, L.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n BMJ Open, 9(6): e028098. June 2019.\n Number: 6\n\n\n\n
\n\n\n\n \n \n $\"Protocol$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{bird_protocol_2019,\n\ttitle = {Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold},\n\tvolume = {9},\n\tissn = {2044-6055, 2044-6055},\n\turl = {http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-028098},\n\tdoi = {10.1136/bmjopen-2018-028098},\n\tabstract = {Introduction\n              The common cold is the most common infectious disease affecting humans. It is usually a self-limiting disease; however, the common cold can cause significant morbidity and has a substantial economic impact on society. Human rhinoviruses (HRVs), which cause up to two-thirds of colds, have temperature-dependent replication and most HRV strains replicate optimally at 33°C. Delivery of heated, humidified air to the upper airways has the potential to reduce viral replication, but evidence of the effectiveness of this treatment of the common cold is inconclusive. We plan to test the hypothesis that delivery of humidified air heated to 41°C at high flow, nasal high flow rhinothermy (rNHF), for 2 hours daily for five days is more effective in reducing common cold symptom severity and duration than five days of ‘sham’ rhinothermy.\n            \n            \n              Methods and analysis\n              This is a randomised, single-blind, parallel-group trial comparing rNHF to ‘sham’ rhinothermy in the treatment of common cold. We plan to recruit 170 participants within 48 hours of the onset of symptoms of common cold and randomise them 1:1 to receive one of the two treatments for five days. The study duration is 14 days, which includes clinic visits on the first day of randomisation and four days post-randomisation, and a phone call on the 14th day. Participants will complete daily symptom diaries which include a symptom score, the Modified Jackson Score (MJS). The primary outcome is the MJS after four days.\n            \n            \n              Ethics and dissemination\n              New Zealand Ethics Registration: 17/STH/174. Results will be published in a peer-reviewed medical journal, presented at academic meetings, and reported to participants.\n            \n            \n              Trial registration number\n              U1111-1194-4345 and ACTRN12617001340325; Pre-results.},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2020-08-23},\n\tjournal = {BMJ Open},\n\tauthor = {Bird, Grace and Braithwaite, Irene and Harper, James and McKinstry, Steven and Koorevaar, Iris and Fingleton, James and Semprini, Alex and Dilcher, Meik and Jennings, Lance and Weatherall, Mark and Beasley, Richard},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 6},\n\tpages = {e028098},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n \n Increased risk of mortality with liberal oxygen therapy compared with conservative oxygen therapy in critically ill adults.\n \n \n \n \n\n\n \n Beasley, R.; and Mackle, D.\n\n\n \n\n\n\n BMJ Evidence-Based Medicine, 24(3): 113–114. June 2019.\n Number: 3\n\n\n\n
\n\n\n\n \n \n $\"Increased$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_increased_2019,\n\ttitle = {Increased risk of mortality with liberal oxygen therapy compared with conservative oxygen therapy in critically ill adults},\n\tvolume = {24},\n\tissn = {2515-446X, 2515-4478},\n\turl = {http://ebm.bmj.com/lookup/doi/10.1136/bmjebm-2018-111054},\n\tdoi = {10.1136/bmjebm-2018-111054},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2020-08-23},\n\tjournal = {BMJ Evidence-Based Medicine},\n\tauthor = {Beasley, Richard and Mackle, Diane},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 3},\n\tpages = {113--114},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma.\n \n \n \n \n\n\n \n Beasley, R.; Harper, J.; Bird, G.; Dunphy, H.; Semprini, A.; Pavord, I. D.; Papi, A.; and Weatherall, M.\n\n\n \n\n\n\n BMC Pulmonary Medicine, 19(1): 264. December 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n $\"Dose-response$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_dose-response_2019,\n\ttitle = {Dose-response relationship of {ICS}/fast-onset {LABA} as reliever therapy in asthma},\n\tvolume = {19},\n\tissn = {1471-2466},\n\turl = {https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-019-1014-4},\n\tdoi = {10.1186/s12890-019-1014-4},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {BMC Pulmonary Medicine},\n\tauthor = {Beasley, Richard and Harper, James and Bird, Grace and Dunphy, Harriette and Semprini, Alex and Pavord, Ian D. and Papi, Alberto and Weatherall, Mark},\n\tmonth = dec,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {264},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma.\n \n \n \n \n\n\n \n Beasley, R.; Holliday, M.; Reddel, H. K.; Braithwaite, I.; Ebmeier, S.; Hancox, R. J.; Harrison, T.; Houghton, C.; Oldfield, K.; Papi, A.; Pavord, I. D.; Williams, M.; and Weatherall, M.\n\n\n \n\n\n\n New England Journal of Medicine, 380(21): 2020–2030. May 2019.\n Number: 21\n\n\n\n
\n\n\n\n \n \n $\"Controlled$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_controlled_2019,\n\ttitle = {Controlled {Trial} of {Budesonide}–{Formoterol} as {Needed} for {Mild} {Asthma}},\n\tvolume = {380},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1901963},\n\tdoi = {10.1056/NEJMoa1901963},\n\tlanguage = {en},\n\tnumber = {21},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Beasley, Richard and Holliday, Mark and Reddel, Helen K. and Braithwaite, Irene and Ebmeier, Stefan and Hancox, Robert J. and Harrison, Tim and Houghton, Claire and Oldfield, Karen and Papi, Alberto and Pavord, Ian D. and Williams, Mathew and Weatherall, Mark},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 21},\n\tpages = {2020--2030},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold.\n \n \n \n \n\n\n \n Bird, G.; Braithwaite, I.; Harper, J.; McKinstry, S.; Koorevaar, I.; Fingleton, J.; Semprini, A.; Dilcher, M.; Jennings, L.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n BMJ Open, 9(6): e028098. 2019.\n Number: 6\n\n\n\n
\n\n\n\n \n \n $\"Protocol$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{bird_protocol_2019-1,\n\ttitle = {Protocol for a randomised, single-blind, two-arm, parallel-group controlled trial of the efficacy of rhinothermy delivered by nasal high flow therapy in the treatment of the common cold},\n\tvolume = {9},\n\tissn = {2044-6055},\n\turl = {http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-028098},\n\tdoi = {10.1136/bmjopen-2018-028098},\n\tnumber = {6},\n\tjournal = {BMJ Open},\n\tauthor = {Bird, Grace and Braithwaite, Irene and Harper, James and McKinstry, Steven and Koorevaar, Iris and Fingleton, James and Semprini, Alex and Dilcher, Meik and Jennings, Lance and Weatherall, Mark and Beasley, Richard},\n\tyear = {2019},\n\tnote = {Number: 6},\n\tpages = {e028098},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Nasal high‐flow therapy compared with non‐invasive ventilation in COPD patients with chronic respiratory failure: A randomized controlled cross‐over trial.\n \n \n \n\n\n \n McKinstry, S.; Singer, J.; Pieter Baarsma, J.; Weatherall, M.; Beasley, R.; and Fingleton, J.\n\n\n \n\n\n\n Respirology. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{mckinstry_nasal_2019-1,\n\ttitle = {Nasal high‐flow therapy compared with non‐invasive ventilation in {COPD} patients with chronic respiratory failure: {A} randomized controlled cross‐over trial},\n\tdoi = {10.1111/resp.13575},\n\tjournal = {Respirology},\n\tauthor = {McKinstry, Steven and Singer, Joseph and Pieter Baarsma, Jan and Weatherall, Mark and Beasley, Richard and Fingleton, James},\n\tyear = {2019},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Cannabis-based medicinal products and the role of the doctor: should we be cautious or cautiously optimistic?.\n \n \n \n\n\n \n Braithwaite, I.; Newton-Howes, G.; Oldfield, K.; and Semprini, A.\n\n\n \n\n\n\n The New Zealand Medical Journal, 132(1500): 82–88. 2019.\n Number: 1500\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n

\n

@article{braithwaite_cannabis-based_2019,\n\ttitle = {Cannabis-based medicinal products and the role of the doctor: should we be cautious or cautiously optimistic?},\n\tvolume = {132},\n\tissn = {1175-8716},\n\tshorttitle = {Cannabis-based medicinal products and the role of the doctor},\n\tabstract = {With rapidly changing legislation designed to improve access to cannabis-based medicinal products, we assess the obligations of the law and professional bodies on the proposed prescribers of these products. We argue that the current legal and professional obligations may limit prescribing practices despite legislative change, and that without the usual licensing processes of Medsafe being applied to these products, prescribers and their professional bodies must engage in the process of change to ensure short- and long-term patient safety and to maintain professional standards.},\n\tlanguage = {eng},\n\tnumber = {1500},\n\tjournal = {The New Zealand Medical Journal},\n\tauthor = {Braithwaite, Irene and Newton-Howes, Giles and Oldfield, Karen and Semprini, Alex},\n\tyear = {2019},\n\tpmid = {31415502},\n\tnote = {Number: 1500},\n\tkeywords = {Humans, Marijuana Use, Medical Marijuana, New Zealand, Patient Safety, Physician's Role, Physicians, Practice Patterns, Physicians'},\n\tpages = {82--88},\n}\n\n

\n

\n\n\n\n\n\n

\n \n\n \n \n \n \n \n Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: A randomised controlled trial.\n \n \n \n\n\n \n Semprini, A.; Singer, J.; Braithwaite, I.; Shortt, N.; Thayabaran, D.; McConnell, M.; Weatherall, M.; and Beasley, R.\n\n\n \n\n\n\n BMJ Open, 9: e026201. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{semprini_kanuka_2019,\n\ttitle = {Kanuka honey versus aciclovir for the topical treatment of herpes simplex labialis: {A} randomised controlled trial},\n\tvolume = {9},\n\tdoi = {10.1136/bmjopen-2018-026201},\n\tjournal = {BMJ Open},\n\tauthor = {Semprini, Alex and Singer, Joseph and Braithwaite, Irene and Shortt, Nick and Thayabaran, Darmiga and McConnell, Melanie and Weatherall, Mark and Beasley, Richard},\n\tyear = {2019},\n\tpages = {e026201},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Pragmatic Randomized Controlled Trial of Budesonide/Formoterol Reliever Therapy in Adults with Mild Asthma.\n \n \n \n\n\n \n Beasley, R W; Holliday, M; Reddel, H K; Braithwaite, I; Ebmeier, S; Hancox, R; Harrison, T; Houghton, C; Oldfield, K; and Papi, A\n\n\n \n\n\n\n In D101. CLINICAL AND TRANSLATIONAL STUDIES IN ASTHMA AND COPD, pages A7477–A7477. American Thoracic Society, 2019.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@incollection{beasley_pragmatic_2019,\n\ttitle = {Pragmatic {Randomized} {Controlled} {Trial} of {Budesonide}/{Formoterol} {Reliever} {Therapy} in {Adults} with {Mild} {Asthma}},\n\tisbn = {1073-449X},\n\tbooktitle = {D101. {CLINICAL} {AND} {TRANSLATIONAL} {STUDIES} {IN} {ASTHMA} {AND} {COPD}},\n\tpublisher = {American Thoracic Society},\n\tauthor = {Beasley, R W and Holliday, M and Reddel, H K and Braithwaite, I and Ebmeier, S and Hancox, R and Harrison, T and Houghton, C and Oldfield, K and Papi, A},\n\tyear = {2019},\n\tpages = {A7477--A7477},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Practice patterns and perceptions of Australian and New Zealand anaesthetists towards perioperative oxygen therapy.\n \n \n \n\n\n \n R Frei, D.; Beasley, R.; Campbell, D.; Leslie, K.; Merry, A.; Moore, M.; S Myles, P.; Ruawai-Hamilton, L.; G Short, T.; and Young, P.\n\n\n \n\n\n\n Anaesthesia and Intensive Care,0310057X1984224. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{r_frei_practice_2019,\n\ttitle = {Practice patterns and perceptions of {Australian} and {New} {Zealand} anaesthetists towards perioperative oxygen therapy},\n\tdoi = {10.1177/0310057X19842245},\n\tjournal = {Anaesthesia and Intensive Care},\n\tauthor = {R Frei, Daniel and Beasley, Richard and Campbell, Douglas and Leslie, Kate and Merry, Alan and Moore, Matthew and S Myles, Paul and Ruawai-Hamilton, Laura and G Short, Tim and Young, Paul},\n\tyear = {2019},\n\tpages = {0310057X1984224},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Triaging treatable traits in asthma.\n \n \n \n\n\n \n Baggott, C.; and Beasley, R.\n\n\n \n\n\n\n Respirology, 24(1): 5–6. 2019.\n Number: 1 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{baggott_triaging_2019,\n\ttitle = {Triaging treatable traits in asthma},\n\tvolume = {24},\n\tissn = {1323-7799},\n\tnumber = {1},\n\tjournal = {Respirology},\n\tauthor = {Baggott, Christina and Beasley, Richard},\n\tyear = {2019},\n\tnote = {Number: 1\nPublisher: Wiley Online Library},\n\tpages = {5--6},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Asthma paradoxes: time for a new approach across the spectrum of asthma severity.\n \n \n \n\n\n \n Beasley, R.; Bird, G.; Harper, J.; and Weatherall, M.\n\n\n \n\n\n\n European Respiratory Journal, 53: 1900218. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_asthma_2019,\n\ttitle = {Asthma paradoxes: time for a new approach across the spectrum of asthma severity},\n\tvolume = {53},\n\tdoi = {10.1183/13993003.00218-2019},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Beasley, Richard and Bird, Grace and Harper, James and Weatherall, Mark},\n\tyear = {2019},\n\tpages = {1900218},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Treatable Traits: a new paradigm for 21 st century management of chronic airway diseases.\n \n \n \n\n\n \n Mcdonald, V.; Fingleton, J.; Agusti, A.; A. Hiles, S.; Clark, V.; E. Holland, A.; B. Marks, G.; P. Bardin, P.; Beasley, R.; D. Pavord, I.; A. B. Wark, P.; and G. Gibson, P.\n\n\n \n\n\n\n European Respiratory Journal, 53: 1802058. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{mcdonald_treatable_2019-1,\n\ttitle = {Treatable {Traits}: a new paradigm for 21 st century management of chronic airway diseases},\n\tvolume = {53},\n\tdoi = {10.1183/13993003.02058-2018},\n\tjournal = {European Respiratory Journal},\n\tauthor = {Mcdonald, Vanessa and Fingleton, James and Agusti, Alvar and A. Hiles, Sarah and Clark, Vanessa and E. Holland, Anne and B. Marks, Guy and P. Bardin, Philip and Beasley, Richard and D. Pavord, Ian and A. B. Wark, Peter and G. Gibson, Peter},\n\tyear = {2019},\n\tpages = {1802058},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Fever control in critically ill adults. An individual patient data meta-analysis of randomised controlled trials.\n \n \n \n\n\n \n Young, P.; Bellomo, R.; R. Bernard, G.; J. Niven, D.; Schortgen, F.; Saxena, M.; Beasley, R.; and Weatherall, M.\n\n\n \n\n\n\n Intensive Care Medicine, 45. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{young_fever_2019-1,\n\ttitle = {Fever control in critically ill adults. {An} individual patient data meta-analysis of randomised controlled trials},\n\tvolume = {45},\n\tdoi = {10.1007/s00134-019-05553-w},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Young, Paul and Bellomo, Rinaldo and R. Bernard, Gordon and J. Niven, Daniel and Schortgen, Frédérique and Saxena, Manoj and Beasley, Richard and Weatherall, Mark},\n\tyear = {2019},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n The Immunological Mysteries of Tuberculosis.\n \n \n \n\n\n \n Sabbagh, D. K; Beasley, R.; and Marks, G. B\n\n\n \n\n\n\n The Journal of Allergy and Clinical Immunology: In Practice, 7(2): 649–650. 2019.\n Number: 2 Publisher: Elsevier\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{sabbagh_immunological_2019-1,\n\ttitle = {The {Immunological} {Mysteries} of {Tuberculosis}},\n\tvolume = {7},\n\tissn = {2213-2198},\n\tnumber = {2},\n\tjournal = {The Journal of Allergy and Clinical Immunology: In Practice},\n\tauthor = {Sabbagh, Doñah K and Beasley, Richard and Marks, Guy B},\n\tyear = {2019},\n\tnote = {Number: 2\nPublisher: Elsevier},\n\tpages = {649--650},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Inhaled Corticosteroid Therapy in Adult Asthma: Time for a New Therapeutic Dose Terminology.\n \n \n \n\n\n \n Beasley, R.; Harper, J.; Bird, G.; Maijers, I.; Weatherall, M.; and D Pavord, I.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_inhaled_2019,\n\ttitle = {Inhaled {Corticosteroid} {Therapy} in {Adult} {Asthma}: {Time} for a {New} {Therapeutic} {Dose} {Terminology}},\n\tdoi = {10.1164/rccm.201810-1868CI},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Beasley, Richard and Harper, James and Bird, Grace and Maijers, Ingrid and Weatherall, Mark and D Pavord, Ian},\n\tyear = {2019},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Prospective observational study in patients with obstructive lung disease: NOVELTY design.\n \n \n \n\n\n \n Reddel, H. K; de Verdier, M. G.; Agustí, A.; Anderson, G.; Beasley, R.; Bel, E. H; Janson, C.; Make, B.; Martin, R. J; and Pavord, I.\n\n\n \n\n\n\n ERJ open research, 5(1): 36–2018. 2019.\n Number: 1 Publisher: Eur Respiratory Soc\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{reddel_prospective_2019-1,\n\ttitle = {Prospective observational study in patients with obstructive lung disease: {NOVELTY} design},\n\tvolume = {5},\n\tissn = {2312-0541},\n\tnumber = {1},\n\tjournal = {ERJ open research},\n\tauthor = {Reddel, Helen K and de Verdier, Maria Gerhardsson and Agustí, Alvar and Anderson, Gary and Beasley, Richard and Bel, Elisabeth H and Janson, Christer and Make, Barry and Martin, Richard J and Pavord, Ian},\n\tyear = {2019},\n\tnote = {Number: 1\nPublisher: Eur Respiratory Soc},\n\tpages = {36--2018},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n \n STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury: Study Protocol for a Multi-National, Multi-Center, Randomized Controlled Trial.\n \n \n \n \n\n\n \n Investigators, T. S.\n\n\n \n\n\n\n Canadian Journal of Kidney Health and Disease, 6: 205435811985293. 2019.\n \n\n\n\n
\n\n\n\n \n \n $\"STandard$ Paper\n \n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{investigators_standard_2019,\n\ttitle = {{STandard} versus {Accelerated} initiation of {Renal} {Replacement} {Therapy} in {Acute} {Kidney} {Injury}: {Study} {Protocol} for a {Multi}-{National}, {Multi}-{Center}, {Randomized} {Controlled} {Trial}},\n\tvolume = {6},\n\tissn = {2054-3581},\n\turl = {http://journals.sagepub.com/doi/10.1177/2054358119852937},\n\tdoi = {10.1177/2054358119852937},\n\tjournal = {Canadian Journal of Kidney Health and Disease},\n\tauthor = {Investigators, The Starrt-aki},\n\tyear = {2019},\n\tpages = {205435811985293},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Oxygen: a new look at an old therapy.\n \n \n \n\n\n \n Beasley, R.; Mackle, D.; and Young, P.\n\n\n \n\n\n\n Journal of the Royal Society of New Zealand,1–17. 2019.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n \n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{beasley_oxygen_2019,\n\ttitle = {Oxygen: a new look at an old therapy},\n\tdoi = {10.1080/03036758.2019.1566154},\n\tjournal = {Journal of the Royal Society of New Zealand},\n\tauthor = {Beasley, Richard and Mackle, Diane and Young, Paul},\n\tyear = {2019},\n\tpages = {1--17},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n What Happens to Nutrition Intake in the Post–Intensive Care Unit Hospitalization Period? An Observational Cohort Study in Critically Ill Adults.\n \n \n \n\n\n \n Ridley, E. J; Parke, R. L; Davies, A. R; Bailey, M.; Hodgson, C.; Deane, A. M; McGuinness, S.; and Cooper, D J.\n\n\n \n\n\n\n Journal of Parenteral and Enteral Nutrition, 43(1): 88–95. 2019.\n Number: 1 Publisher: Wiley Online Library\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{ridley_what_2019-1,\n\ttitle = {What {Happens} to {Nutrition} {Intake} in the {Post}–{Intensive} {Care} {Unit} {Hospitalization} {Period}? {An} {Observational} {Cohort} {Study} in {Critically} {Ill} {Adults}},\n\tvolume = {43},\n\tissn = {0148-6071},\n\tnumber = {1},\n\tjournal = {Journal of Parenteral and Enteral Nutrition},\n\tauthor = {Ridley, Emma J and Parke, Rachael L and Davies, Andrew R and Bailey, Michael and Hodgson, Carol and Deane, Adam M and McGuinness, Shay and Cooper, D James},\n\tyear = {2019},\n\tnote = {Number: 1\nPublisher: Wiley Online Library},\n\tpages = {88--95},\n}\n\n

\n

\n\n\n\n

\n \n\n \n \n \n \n \n Research nurses in New Zealand intensive care units: A qualitative descriptive study.\n \n \n \n\n\n \n Mackle, D.; and Nelson, K.\n\n\n \n\n\n\n Australian Critical Care, 32(2): 148–154. 2019.\n Number: 2 Publisher: Elsevier\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n \n \n\n bibtex\n \n\n \n\n \n \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n \n \n \n\n\n\n

\n

@article{mackle_research_2019-1,\n\ttitle = {Research nurses in {New} {Zealand} intensive care units: {A} qualitative descriptive study},\n\tvolume = {32},\n\tissn = {1036-7314},\n\tnumber = {2},\n\tjournal = {Australian Critical Care},\n\tauthor = {Mackle, Diane and Nelson, Katherine},\n\tyear = {2019},\n\tnote = {Number: 2\nPublisher: Elsevier},\n\tpages = {148--154},\n}\n

\n

\n\n\n\n